The Japan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure.
June 25, 2007 (Press Release) --
Independent 5-year pharmaceutical and healthcare industry forecasts for Japan.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Japanese pharmaceutical and healthcare industry.
Competitive intelligence, Japanese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Japanese market.
The Japan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Japan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Japanese pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Japan to test other views – a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Japanese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Japan.
Exploit The Latest Competitive Japanese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Japan.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
For more information, please visit:
http://www.bharatbook.com/detail.asp?id=18705
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Japanese pharmaceutical and healthcare industry.
Competitive intelligence, Japanese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Japanese market.
The Japan Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Japan Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Japanese pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Japan to test other views – a key input for successful budgeting and strategic business planning in the Japanese pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Japanese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Japan.
Exploit The Latest Competitive Japanese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Japan.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
For more information, please visit:
http://www.bharatbook.com/detail.asp?id=18705
Email
Print
SPAM
